 ;templatestyles src="Chembox/styles.css"/ ;
Chemical compound
Enzastaurin is a synthetic bisindolylmaleimide with potential antineoplastic activity. Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply, preventing growth.
Trials.
In 2013 it failed a phase III clinical trial for lymphoma.
In 2022, there is an upcoming initial trial called PREVEnt to look into the effectiveness of Enzastaurin for the treatment of Vascular Elhers-Danlos syndrome (vEDS). 
References.
 ;templatestyles src="Reflist/styles.css" / ;